NanoString Raises $20M to Advance Breast Cancer Test, Tech Development
November 08, 2011
NanoString Raises $20M to Advance Breast Cancer Test, Tech Development
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- NanoString on Track to Launch Breast Cancer Subtyping Test in EU with CE Mark, in US with FDA OK
August 15, 2012 / Pharmacogenomics Reporter - Bioclassifier, NanoString to 'Decentralize' Breast Cancer Test as ARUP Preps qPCR Version
December 9, 2010 / PCR Insider - NanoString Establishes Dx Unit as Breast Cancer Test Moves Closer to FDA Submission
May 29, 2012 / BioArray News - IP Update: GE Healthcare; Stevens Institute of Technology; Quest Diagnostics; Agilent Technologies; and More
January 10, 2012 / BioArray News - NanoString Study Suggests PAM50 Recurrence Test Provides Advantages over Oncotype DX
December 14, 2011 / Pharmacogenomics Reporter